scholarly journals The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

2019 ◽  
Vol 24 (9) ◽  
Author(s):  
Emne A. Abdallah ◽  
Alexcia C. Braun ◽  
Bianca C.T.C.P. Flores ◽  
Laís Senda ◽  
Ana Cláudia Urvanegia ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Implications ◽  
Circulating Tumor Microemboli

scholarly journals Platelet-Lymphocyte Ratio, Circulating Tumor Cells and Circulating Tumor Microemboli as Predictors of Thrombosis in Patients with Gastric Cancer

2021 ◽  
pp. 1-8
Author(s):  
Bruno Soriano Pignataro ◽  
Bruno Soriano Pignataro ◽  
Emne Ali Abdallah ◽  
Vinicius Fernando Calsavara ◽  
Celso Abdon Lopes Mello ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Neoadjuvant Treatment ◽  
Progression Free Survival ◽  
Prognostic Indicator ◽  
Assessment Tools ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio ◽  
Circulating Tumor Microemboli

Background: Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology patients. There are no accurate risk assessment tools to predict venous thromboembolism (VTE). Circulating tumor cells (CTCs), circulating tumor microemboli (CTM), and high platelet-lymphocyte ratio (PLR) may predispose to VTE. Objective: To evaluate correlations of CTCs, CTM, and PLR with VTE and progression-free survival (PFS) in gastric cancer patients. Methods: Patients with gastric cancer were recruited (March 2016 to April 2017). CTCs were assayed by ISET at two timepoints: before neoadjuvant treatment (CTC1) and after surgery/before adjuvant therapy (CTC2) for patients with localized disease, and before first-line chemotherapy (CTC1) and after 6 months (CTC2) for patients with metastases. VTE incidence was determined retrospectively. PFS was estimated by Kaplan-Meier analysis. Results: We studied 93 patients. According to Khorana scores, 63 (67.7%) patients were at intermediate and 30 (32.3%) were at high risk for VTE. VTE incidence was 20.4% and CTM were found in 39.8%. VTE developed in 7/37 (18.9%) CTM-positive and in 11/50 (22%) CTM-negative patients (p=0.93). When PLR >288, VTE occurred in 7/14 patients (p=0.005). PLR also associated with poor PFS (p<0.0001). CTC2 was associated with poor PFS (p<0.0001). CTC2, PLR and VTE were independent prognostic factors for PFS (p=0.005, 0.043, and <0.0001 respectively). Conclusion: PLR is a prognostic indicator for PFS and for VTE in gastric cancer. Neither CTC, nor CTM improved risk stratification for VTE in our population.

scholarly journals Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

2017 ◽  
Vol 10 (3) ◽  
pp. 431-441 ◽  
Author(s):  
Xiumei Zheng ◽  
Li Fan ◽  
Pengfei Zhou ◽  
Hong Ma ◽  
Shaoyi Huang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Circulating Tumor Microemboli

scholarly journals Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer

Oncotarget ◽  
2014 ◽  
Vol 5 (16) ◽  
pp. 6594-6602 ◽  
Author(s):  
Yilin Li ◽  
Xiaotian Zhang ◽  
Sai Ge ◽  
Jing Gao ◽  
Jifang Gong ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Significance

scholarly journals Biology, detection, and clinical implications of circulating tumor cells

2014 ◽  
Vol 7 (1) ◽  
pp. 1-11 ◽  
Author(s):  
Simon A Joosse ◽  
Tobias M Gorges ◽  
Klaus Pantel
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Implications

scholarly journals Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications

2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
Georg Lurje ◽  
Marc Schiesser ◽  
Andreas Claudius Hoffmann ◽  
Paul Magnus Schneider
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Disease Progression ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Response To Therapy ◽  
Clinical Implications ◽  
Gastrointestinal Malignancies ◽  
Progression Of Disease

Since their introduction more than 50 years by Engell, circulating tumor cells (CTCs) have been evaluated in cancer patients and their detection has been correlated with clinical outcome, in esophageal, gastric, and colorectal cancer. With the availability of refined technologies, the identification of CTCs from peripheral blood is emerging as a useful tool for the detection of malignancy, monitoring disease progression, and measuring response to therapy. However, increasing evidence suggests a variety of factors to be responsible for disease progression. The analysis of a single CTC marker is therefore unlikely to accurately predict progression of disease with sufficient resolution and reproducibility. Here we discuss the current concept of CTCs, summarize the available techniques for their detection and characterization, and aim to provide a comprehensive update on the clinical implications of CTCs in gastrointestinal (GI) malignancies.

Sign in / Sign up

Export Citation Format

Share Document